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Introduction
 Sceletium tortuosum (L.) N.E.Br. is a plant 
native to South Africa, specifically occurring in 
the southwestern parts of the Cape Province and 
Namaqualand. The use of kougoed (something 
to chew) or Kanna, a concoction prepared from 
S.tortuosum has been recorded in the literature for over 
300 years (Scott and Hewett, 2008). The traditional 
method for preparing kougoed involves crushing the 
whole plant, including the roots, between stones after 
harvesting. The crushed material is placed in a skin 
or canvas bag which is closed and left to “ferment” 
in the sun. After 2-3 days, the bag is opened and the 
contents mixed, and thereafter sealed and left in the 
sun for a few more days. Eight days after crushing the 
material, the bag is opened and the kougoed is spread 
out to dry in the sun. The finished product is light 
brown and somewhat stringy in appearance (Smith et 
al., 1996; Smith et al., 1998).   
As the name suggests, the fermented and dried 
material was chewed. There are also some reports of 
it being used as a tea or a snuff  (Watt and Breyer-
Brandwijk, 1962). In the earliest written records of its 
use, kougoed is described as having mood enhancing 
and stimulant properties (Scott and Hewett, 2008). 
Most people describe an anxiolytic effect, relaxation 
with no cognitive impairment, a feeling of tranquil 
mellowness, enhanced social intercourse and less 
inhibition. Some say it is good for stomach ailments, 
can cause anaesthesia of the jaw, can relieve pain and 
alleviate hunger. Recently a patent has been taken 
out on pharmaceutical compositions made from 
S.tortuosum for the treatment of depression, anxiety, 
alcohol and drug dependence, bulimia nervosa and 
obsessive-compulsive disorder  (Gericke and van 
Wyk, 2001). 
 In 2001 an US patent was granted for the use of 
pharmaceutical compositions made from S.tortuosum 
to treat various ailments (Gericke and van Wyk, 2001). 
The patent was granted on the basis of the potent 
serotonin-uptake inhibitory activity demonstrated for 
the crude plant extract, mesembrine, mesembranol 
and mesembrenone. They have the similar potentcy 
as the tricyclic antidepressant imipramine HCl.
 The potent serotonin-uptake inhibitory activity 
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demonstrated for extracts of S.tortuosum and its 
major alkaloids can certainly account for the effects 
of this plant material and some of its therapeutic 
potentials. However, secondary metabolites are often 
multi-functional compounds (van Wyk and Wink, 
2004) and they often affect more than one target in 
the body. Also, crude plant extracts or plant material 
traditionally consumed by ingestion contains many 
compounds which may affect many targets in the 
body simultaneously. Complex mixtures of chemical 
compounds may have numerous, synergistic effects 
on various organ systems in the body. The overall 
effect may be stronger than that of only one compound 
alone. Minor metabolites can affect targets that 
have a balancing effect that can for example cause 
fewer side effects as compared to a synthetic pure 
pharmaceutical. It is of interest to know which other 
biological activities a certain plant or compound has, 
as it could give clues to more potential therapeutic 
uses besides that already known. Therefore, it is also 
interesting to investigate other biological activities in 
an attempt to see through which mechanisms a herbal 
medicine may have its effect. Sceletium and kougoed 
seems to be a promising treatment for mood and 
anxiety-related disorders, but still requires further 
studies to understand the activity. 
 The cannabinoid system is one of the most 
recently discovered receptor systems in the human 
body.  To date, two receptors CB 1 and CB2 have been 
identified. Evidence is mounting for the existence of 
one or more additional cannabinoid receptors (Begg 
et al., 2005). Cannabinoid receptors CB1 and CB2 
are both G-protein coupled receptors. In the brain, 
endocannabinoids behave as retrograde signaling 
messengers that stimulate presynaptic CB1 receptors 
on neurons. This activation results in inhibition of 
adenylate cyclase activity, regulation of ion channel 
activities and activation of the mitogen-activated 
protein kinase cascade (Matsuda et al., 1990). The 
signal transduction mechanisms have been reviewed 
by Howlett et al. (2004). CB1 receptors are the most 
abundant receptors in the mammalian brain, and also 
occur at lower concentrations in other peripheral 
tissues and cells such as testis, eye, urinary bladder, 
ileum and adipocytes (Lange and Kruse, 2005; 
Pertwee, 1997). CB2 is found mostly in cells of the 
immune and hematopoietic systems (Munro et al., 
1993), but has also been found in the brain, liver, 
pancreas and in bone (Juan-Pico et al., 2005; Julien 
et al., 2005; Karzak et al., 2005; Van Sickle et al., 
2005). 
 CB1 receptors are found in brain areas related 
to perception of emotions (Howlett et al., 2004) and 
control of anxiety (Pistis et al., 2004). Support for 
the hypothesis that the endocannabinoid system is 
important for regulation of mood and anxiety states 
have been provided by data from neurobiological, 
pharmacological and genetic studies (Witkin et al., 
2005b). Blockage or antagonism of CB1 receptors 
have produced antidepressant effects, and have also 
been associated with enhancement of cognition and 
efficacy against drug addiction disorders, which are 
often comorbid with depression (Witkin et al., 2005a). 
CB1 receptors have been found co-distributed with 
5-HT transporters in the amygdale of rat brains, and 
there is evidence to suggest that they mediate 5-HT 
release (Ashton et al., 2006). 
 The CB1 receptor therefore seems like a promising 
target for the treatment of disorders related to mood, 
anxiety and cognition. The CB1 receptor has also been 
identified as a possible target for pharmacotherapy of 
pain and inflammation, other central nervous system 
disorders, nausea, cardiovascular and respiratory 
disorders, eye disorders, cancer, gastrointestinal 
disorders, and musculoskeletal disorders (Pacher et 
al., 2006). 
 Another strategy for a treatment of nervous 
system disorders is inhibition of acetylcholinesterase 
(E.C. 3.1.1.7; AChE).  This enzyme is one of 
two cholinesterase enzymes that occur in the 
human central nervous system. AChE hydrolyses 
acetylcholine at cholinergic synapses to terminate 
nerve impulse transmission. Inhibition of AChE 
activity increases the availability of acetylcholine 
to sustain nerve cell communications, therefore 
chemical inhibitors as possible leads for nervous 
system disorders is being searched for (Lenta et al., 
2008). Inhibition of AChE has been a strategy for 
treatment of senile dementia, ataxia, myasthenia 
gravis and Parkinson’s disease (Mukherjee et al., 
2007), but probably the most attention has been given 
to finding AChE inhibitors to treat Alzheimers disease 
(AD). An overlapping distribution of CB1 receptors 
with nicotinic acetylcholine (nACh) receptors have 
been found in brain areas considered important for 
memory modulation (Cohen et al., 2002). 
 The goal of this study is to find further scientific 
evidence for the traditional use of  S.tortuosum 
extracts to have enhancing and stimulant properties 
by testing the extract on CB1 receptor binding assay. 
The study also included the testing of the extract in 
the AChE inhibitory assay in order to evaluate the 
potential of this extract to improve cognitive function 
and memory.
Materials and Methods
Plant material
Cannabinoid CB1 receptor binding and acetylcholinesterase inhibitory activity of Sceletium tortuosum L. 351
International Food Research Journal 17: 349-355
 Plant material was purchased from a community 
project where S.tortuosum is grown for commercial 
use. Plants were grown at Helpmekaar, Calvinia, 
in the Northern Cape province of South Africa. 
Plants were harvested in October, and kougoed was 
prepared from it according to the traditional method. 
Plant material was also purchased that had not been 
processed in the traditional way, but only dried and 
not ground up. 
Preparation of extracts
800 mg kougoed was extracted with 4 ml each 
of n- hexane, chloroform and methanol by sonication 
for 15 min. The extracts were centrifuged for 10 min 
at 20000x at 24 ºC. The supernatant was collected 
and evaporated to dryness under reduced pressure at 
40 ºC. The extracts were weighed and redissolved in 
DMSO to a concentration of 1 mg/ml. Also included 
in the assay were the alkaloid extracts from kougoed 
and unfermented plant material and mesembrine 
at concentrations of 1 mg/ml in DMSO. The final 
concentration of extracts in the assay was 0.037 mg/
ml. 
For alkaloid extract preparation, 5 g each of 
kougoed and unprocessed plant material was de-fatted 
by washing with 20 ml n-hexane three times. The 
material was extracted three times with 50 ml 0.05 M 
H2SO4 for one hour. After filtration the acidic water 
extracts were pooled and basified using NH4OH to 
pH 11. The basic aqueos phase was partitioned three 
times against an equal volume of dichloromethane. 
The organic fractions were pooled and dried under 
reduced pressure at 40 ºC.
Cannabinoid CB1 receptor binding assay
To each reaction tube 250 µl of incubation buffer 
(20 mM Hepes; 5 mM MgCl2; 1 mM EDTA; BSA 
(0.3%), 20 µl of sample as well as 20 µl of the 
radioactive ligand [3H]-CP55940 (8x10-11 M) was 
added. After adding 250 µl of CB1 receptor (Cloned 
Cannabinoid Receptor Subtype 1, Human Sf9 cells, 
Perkin Elmer) the reaction tubes were incubated for 
60 minutes at 30º C in a waterbath. Filters, soaked for 
one hour in ice cold wash buffer (20 mM Hepes pH 
7.4; BSA (0.01%)) with 1% polyethylenimine were 
placed in a Millipore vacuum manifold and washed 
once with wash buffer. After incubation, the reaction 
tubes were filled with wash buffer and the contents 
of the tubes poured over the filters. The tubes were 
refilled with wash buffer and the filters washed again. 
The filters were placed in a counting vile to which 7.5 
ml scintillation fluid (Perkin Elmer: Ultima gold) was 
added. After shaking the counting vile for one minute 
the vials were placed in a scintillation counter. 
For a control to see 100% radioligand binding (total 
binding), a sample was included with no plant extract 
and just DMSO. To determine nonspecific binding a 
sample of excess unlabeled CP55940 (Perkin Elmer) 
was used. The amount of radiolabel specifically 
bound in the absence of competing compounds was 
calculated by subtracting non-specific binding from 
total binding. The percentage of specific binding was 
then calculated for the amount of radiolabel bound in 
the presence of each competing extract or compound. 
To see how much of the receptors were occupied with 
each sample the following equation was used: 
Acetylcholinesterase inhibition assay
AChE inhibitory activity was detected by a TLC- 
and microplate assay based on Ellman’s method 
(Ellman et al., 1961), as described by Rhee et al. 
(2001). 
Gas Chromatography-mass spectrometry (GC-MS)
GC/MS was carried out using a Varian Saturn 
2000 ion trap Gas chromatography mass spectrometer 
with 3800 Chromatograph fitted with a VA5 MS 
column (30m x 0.25mm, 0.25µ film thickness) The 
mass detector was operated in EI mode at 70eV. The 
column temperature started at 175ºC and increased 
to 270ºC at 3ºC /min. Injector temperature was set 
at 270ºC, and detector temperature at 280ºC. The 
column limit was 271ºC.  For sample analysis, 3μl of 
a 2 mg/ml methanol solution was injected. Methanol 
(3μl) was injected as a blank.
Results and Discussion
Cannabinoid CB1 binding
The CB1 receptor binding assay that was 
performed is a screening test for interaction of 
extracts or compounds with this receptor. In this 
assay, experiments were carried out for the different 
extracts. As shown in Table 1, the methanol extract 
displaced just over 22% of the radioligand. The 
n-hexane extract displaced more but usually the 
n-hexane extracts of plant material contains non-
polar compounds that give false positive results in 
this assay. The chloroform extract tested gave very 
weak displacement of the radioligand, confirming 
that non-polar compounds were most likely not 
responsible for the activity seen in the crude extracts. 
The highest activity was shown in the alkaloid extract 
from unprocessed plant material. Lower activity was 
% binding of sample = 100 – [3H] CP55940 specific 
binding in presence of 
sample.
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Sample % binding of sample
Control (DMSO) 0
Methanol extract 22.26 ± 0.81
n-hexane extract 33.52 ± 0.90
Chloroform extract 5.55 ± 0.64
Unfermented alkaloid extract 27.58 ± 1.87
Fermented alkaloid extract 17.73 ± 1.54
Mesembrine 11.64 ± 0.80
THC 70.92 ± 0.82
Unlabelled ligand 100
 
mesembrine 
mesembrine 
mesembrenone 
mesembrenone 
mesembrenol 
mesembranol 
a 
b 
 
Compounds Retention time (min) Mass Fragmentation
Mesembrine 15.5 m/z: 289 (40%, M+), 288 (72%, M-1), 274 (15%), 218 (100%), 204 (52%), 160 (5%), 96 (45%), 70 (17%).
Mesembrenone 16.0 m/z: 287 (100%, M+), 230 (34%), 219 (33%), 204 (16%), 115 (19%), 70 (92%). 
Mesembrenol 17.9
m/z: 289 (18%, M+), 288 (43%), 262 (30%), 261 (37%), 246 
(100%), 230 (37%), 218 (30%), 204 (23%), 164 (50%), 77 
(31%), 60 (47%).
Mesembranol. 18.3 m/z: 291 (3%, M+), 290 (10%), 234 (100%), 204 (2%), 163 (46%). 
Table 1. Results of cannabinoid CB1 assay. Samples and 
THC  at final concentration of 0.037 and 0.0037 mg/ml, 
respectively.
Table 2. Retention time and mass fragmentation of identified constituents  in fermented and unfermented 
alkaloid extracts analyzed by GC-MS.
Figure1. GC-MS chromatograms of alkaloid extracts prepared from 
kougoed (a) and unprocessed plant material (b). Alkaloids were identified 
based on fragmentation patterns and molecular mass, and structures are 
shown.
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seen in the alkaloid extract from processed kougoed, 
which contains more of the major alkaloid and less 
of the minor alkaloids as shown by the results of GC-
MS analysis (Figure 1). 
The alkaloids were identified by comparing 
their fragmentation patterns with those published 
before (Martin et al., 1976). The major alkaloid 
was identified as mesembrine, and the other minor 
alkaloids were mesembrenone, mesembrenol and 
mesembrenol. This identification ware considered 
based on the fragmentation pattern and the retention 
time during GC-MS analysis as shown in Table 2. 
Most in vitro activity studies with CB receptor 
assay have focused on pure synthetic compounds. In 
one study where a plant extract prepared from fruit 
juice was tested for CB1 activity, extracts inhibited 
radioligand binding by 10-14% at concentrations of 1 
mg/ml in the assay (Palu et al., 2008). In the present 
study a crude methanol extract at a of 0.037 mg/ml 
in the assay inhibited radioligand binding twice as 
much. 
Mesembrine on its own showed less activity, 
displacing just over 11% of the radioligand at this 
concentration. Typically, when pure compounds 
are screened in the CB1 assay in high throughput 
screening studies, a concentration of around 0.1-10 
µM is tested in a single point experiment (Foloppe 
et al., 2008; Wang et al., 2008). Usually a range of 
compounds are tested and only ones displacing a 
radioligand such as [3H] CP55940 by more than 50% 
are investigated further. Since mesembrine did not 
show a very high displacement of radioligand, further 
experiments were not carried out to determine IC50 or 
Ki values.
The kougoed alkaloid extract inhibited radioligand 
binding slightly more than the pure mesembrine in 
this assay. The unprocessed material alkaloid extract 
did so even more, inhibiting radioligand binding by 
more than 27%. The differences in activity could 
be due to the different compositions of the alkaloid 
extracts. The alkaloid extract of the unprocessed 
material has mesembrine as the major alkaloid, 
but contains relatively more of the other alkaloids 
(Fig. 1). It is possible that one or more of the minor 
alkaloids interact with the CB1 receptor, and that the 
increased activity seen in the unprocessed alkaloid 
extract is due to their additive effect with mesembrine. 
The methanol extract also displaced more of the 
radioligand than the kougoed alkaloid extract. The 
methanol extract contains some alkaloids, but in a 
much lower concentration than the alkaloid extracts. 
It is possible that compounds other than the alkaloids 
present in the methanol extract are responsible for 
inhibiting the radioligand binding, alone or together 
with the alkaloids. 
     
Acetylcholinesterase inhibition
The AchE microplate assay was performed with 
the alkaloid extracts from kougoed and unprocessed 
plant material, as well as with purified mesembrine. 
The results are shown in Table 3.  The IC50 of the 
alkaloid extracts were estimated from regression 
equations using these data. The two alkaloid extracts 
had similar IC50 values, with that of the kougoed and 
unprocessed material alkaloid extracts being 0.303 
mg/ml and 0.330 mg/ml, respectively. Mesembrine 
was less potent at inhibiting the enzyme, and a 50% 
inhibition was not reached at the concentrations 
tested. The inhibition of the enzyme by galanthamine 
was also tested at three concentrations. It is clear that 
the potency of galanthamine is much higher. 
Mukharjee et al. (2007) tested crude extracts 
of plants known to improve cognitive function and 
memory for AChE activity. These extracts inhibited 
the enzyme with IC50 values of between 0.1 mg/ml 
and 0.15 mg/ml. The activity of these crude extracts 
was higher than our extract.  In the paper of Rhee et al. 
(2001), on which the protocol used in this study was 
based, crude extracts that caused 85-90% inhibition 
of the enzyme at a concentration of 1 mg/ml were 
considered interesting for further investigation. At this 
concentration the alkaloid extracts tested in this study 
satisfied this criterion. At the same concentration (1 
mg/ml) purified mesembrine had an almost three 
times lower activity, even though the alkaloid extracts 
consisted mostly of mesembrine. It is possible that 
the minor alkaloids present in the alkaloid extracts 
are responsible for the higher activity, either through 
a synergistic or additive effect. It was shown in the 
TLC assay that at least three other alkaloids also have 
AChE inhibitory activity (data not shown).
Conclusion
The unprocessed alkaloid extract of S. tortuosum 
was the most active in CB1 receptor binding assay, 
suggesting that a mixture of these alkaloids may have 
a stronger interaction with the CB1 receptor than the 
fermented alkaloid extract and the major alkaloid 
mesembrine. The higher activity of this extract 
may possibly be due to the synergistic effect of the 
alkaloids. The Methanol extract showed a higher 
activity compared to the fermented alkaloid extract. 
It is possible that compounds other than the alkaloids 
present in the methanol extract are responsible for the 
activity. 
Both fermented and unprocessed alkaloid 
extract showed similar activity to inhibit AChE. The 
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activities of both extracts are higher than the activity 
of mesembrine alone. It points to the involvement of 
other alkaloids in the extract to increase the activity. 
These findings confirm that the extract may have 
mood enhancing and stimulant properties which in 
agreement with the traditional use. Moreover, the 
extract is a potential candidate for further studies for 
activity to improve cognitive function and memory.
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